Cell Therapy in Severe Chronic Ischemic Heart Disease

Ministry of Health, Brazil143 enrolled

Overview

Patients with advanced coronary artery disease usually undergo incomplete myocardial revascularization due to the extension and diffuseness of the disease, with very poor distal arterial beds unsuitable for direct revascularization. This study was designed to test the hypothesis that direct, intramyocardial injection of autologous bone marrow cells may further improve myocardial perfusion in patients undergoing incomplete bypass surgery.

All eligible patients will undergo coronary artery bypass grafting (CABG) and, in previously identified areas of viable, ischemic myocardium unsuitable for direct revascularization, be randomized to either placebo (saline) or intramyocardial injection of bone marrow-derived cells (BMC) during surgery. During follow-up, myocardial perfusion assessment will be performed to determine the improvement in treated areas compared to non-treated segments.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

143

Conditions

Chronic Ischemic Heart Disease Coronary Artery Disease Angina Pectoris

Interventions

Cell TherapyPROCEDURE

Intramyocardial injection of autologous bone marrow-derived cells

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * symptoms of angina or angina equivalent * documented coronary artery disease (invasive angiography) * documented myocardial ischemia (stress echo, cardiac scintigraphy, or MRI) * unsuitable for complete myocardial revascularization (PCI or CABG) OR even if a complete procedure in feasible, it is anticipated that myocardial perfusion may not be restored due to poor distal beds Exclusion Criteria: * severe LV dysfunction (EF \< 25% on echo) * short life expectacy (below \< 1 year) * diagnosis of cancer in the past 5 years * diagnosis of hematological diseases * diagnosis of severe heart disease of other etiologies including valvular heart disease, Chagas' disease, etc) * diagnosis of acute coronary syndrome in the past 3 months * diagnosis of chronic kidney disease stage V requiring chronic dialysis

Locations (1)

Heart Institute

São Paulo, São Paulo, Brazil

Outcomes

Primary Outcomes

Increase in myocardial perfusion

Patients will undergo myocardial perfusion assessment by MRI during pharmacological stress with adenosine or dipyridamole. Alternatively, cardiac scintigraphy can be used in patients with contra-indications to MRI.

Time frame: 1, 6 and 12 months

Secondary Outcomes

Improvement in LV function

LV function (global and regional) will be assessed by MRI.

Time frame: 1, 6 and 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.